About Thomas Kim
Thomas Kim is CEO and director at ReEngage Therapeutics.
Form D filings also name Thomas Kim as a president & CEO at EpiVario and sits on its board.
Thomas Kim first appears on SEC filings in 2018.
Experience
This experience comes from Thomas Kim's profile and from SEC filings. For roles taken from filings, the years are when the filings name Thomas Kim in the role, so the role may have started earlier or lasted longer.
ReEngage Therapeutics, Inc. Current
President and CEO (2024 – Present)
Director
2024 – Present · Houston, TX
TF
TANGO2 Research Foundation Current
Member Board of Directors
2023 – Present
GT
Georgia Institute of Technology Current
Advisory Board
2020 – Present
EpiVario Inc. Current
President and CEO (2018 – Present)
Director
2018 – Present · Philadelphia, PA
Develops potential treatments for people with substance use and other psychiatric disorders.
TR
TremeBio
Cofounder and CEO
2025 – 2026
PL
Pathway Consulting Group Ltd
President
2017 – 2026
II
Inovio Pharmaceuticals Inc.
General Counsel and Corporate Secretary
2009 – 2017
IC
Inovio Biomedical Corporation
Senior Director Intellectual Property
2009
VP
VGX Pharmaceuticals
Senior Director Intellectual Property
2007 – 2009
DU
DuPont
Senior Counsel
2005 – 2007
WW
Woodcock Washburn
Attorney
2004 – 2005
RA
Rosenbaum & Associates
Associate attorney
2002 – 2004
ML
Marshall, Gerstein & Borun LLP
Associate attorney
1999 – 2002
PF
Pfizer
Law clerk
1998 – 2000
Key Colleagues at Startups
The people Thomas Kim works with at each company, as listed on that company's latest Form D.
EpiVario Inc. · Form D, Oct 13, 2026
CC
Christopher Cashman
Director
ES
Eric Schultenover
Director